Kichik hujayrali bo'lmagan o'pka saratoni bo'yicha so'nggi yutuq mavjud. Bir turdagi emlash Kichkina hujayrali bo'lmagan o'pka saratonini (NSCLC) davolash mumkin bo'lgan 3-bosqich klinik tasdiqlangan va kichik hujayrali bo'lmagan o'pka kasalligiga katta terapevtik ta'sir ko'rsatadi. Hozir bu juda kam mamlakatlarda mavjud.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung saratonga qarshi emlash relaps bosqichi va rivojlangan (IIIB / IV bosqich) NSCLC bilan og'rigan bemorlarning omon qolish darajasini oshirishi mumkin.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Shubhasiz ramka anga qarshi aniq antikorlar ishlab chiqargandan so'ng antijeni, u asosiy antigenning o'ziga xosligiga qarshi antikorlarni yaratishi mumkin, bu esa chidamli ramkani ichkaridan boshqarishi mumkin. Ushbu o'pkaning zararli o'sishiga qarshi immunizatsiya qilinganidan keyin emlash, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against shish antijenler.
Klinik ravishda o'pka kasalligi isbotlangan emlash juda chidamli va ijro etilishi yaxshiroqdir. Ko'plab asosiy alomatlar mahalliy darajada (infuziya joyida) ro'y beradi va odatda yumshoq va qisqa muddatli bo'ladi. Antikor bemorlarga ahvoli buzilganidan keyin beriladimi-yo'qligidan qat'iy nazar, ularning umumiy chidamliligi yaxshilandi.
Hozirgi vaqtda o'pkaning xavfli o'sishiga qarshi immunizatsiya Hindistonda ilgari surilmagan.
